Date:2/14/2013

r 31, December 31, 2012 2011 $M $M ASSETS Current assets: Cash and cash equivalents 1,482.2 620.0 Restricted cash 17.1 20.6 Accounts receivable, net 824.2 845.0 Inventories 436.9 340.1 Deferred tax asset 229.9 207.6 Prepaid expenses and other current assets 221.8 174.9 Total current assets 3,212.1 2,208.2 Non-current assets: Investments 38.7 29.9 Property, plant and equipment ("PP&E"), net 955.8 932.1 Goodwill 644.5 592.6 Other intangible assets, net 2,388.1 2,493.0 Deferred tax asset 46.5 50.7 Other non-current assets 31.5 73.7 Total assets 7,317.2 6,380.2 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses 1,501.5 1,370.5 Convertible bonds - 1,100.0 Other current liabilities 144.1 63.8 Total current liabilities 1,645.6 2,534.3 Non-current liabilities: Convertible bonds 1,100.0 - Deferred tax liability 520.8 516.6 Other non-current liabilities 241.6 144.3 Total liabilities 3,508.0 3,195.2 Equity: Common stock of 5p par value; 1,000 million shares authorized; and 562.5 million shares issued and outstanding (2011: 1,000 million shares authorized; and 562.5 million shares issued and outstanding) 55.7 55.7 Additional paid-in capital 2,981.5 2,853.3 Treasury stock: 10.7 million shares (2011: 11.8 million) (310.4) (287.2) Accumulated other comprehensive income 86.9 60.3 Retained earnings 995.5 502.9 Total equity 3,809.2 3,185.0 Total liabilities and equity 7,317.2 6,380.2

 

Unaudited US GAAP results for the three months and year to December 31, 2012
Consolidated Statements of Income

3 months to 3 months to Year to Year to December 31, December 31, December 31, December 31, 2012 2011 2012 2011 $M $M $M $M Revenues: Product sales 1,097.6 1,049.2 4,406.7 3,950.2 Royalties 87.2 83.7 241.6 283.5 Other revenues 16.4 9.3 32.9 29.7 Total revenues 1,201.2 1,142.2 4,681.2 4,263.4 Costs and expenses: Cost of product sales(1) 166.6 153.4 645.4 588.1 R&D(1) 281.9 214.4 965.5 770.7 SG&A(1) 6
'/>"/>

SOURCE Shire plc Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related medicine technology :

1. Shire Regenerative Medicine and HealTogether Partner with Celebrity Chef Charles Mattocks to Raise Awareness of Diabetes and its Complications
2. NYSE Hot Stocks Earnings Forecast: Wells Fargo, Eli Lilly, Berkshire Hathaway, Coca-Cola, Valero Energy, and Altria Group
3. Shire Leads New Initiative to Reveal Challenges Facing Rare Disease Community
4. Dr Steven Gillis to Join Shire Board of Directors
5. Shire Second Quarter Product Sales Up 16%
6. Shire Announces that the US Food and Drug Administration has Responded to its Citizen Petition for Adderall XR and has Approved One Abbreviated New Drug Application for Generic Adderall XR
7. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
8. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
9. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
10. Study Delivers Investment Benchmarks across Key New Product Launch Activities in Pharmaceutical Sector
11. SIS Delivers Advanced Interoperability With Siemens Soarian Clinicals To Improve Efficiency, Communication